We showed that DMXAA improved antigen presentation, yet CTL function was compromised, therefore we hypothesized that combining DMXAA with an agonist anti-CD40 antibody that activates DCs (7) or with IL-2 that expands tumor-specific T cells (32) might improve DMXAA efficacy. The gene discussed is IL2; the disease is neoplasm.